Cargando…
Dose Intensive Rituximab and High-Dose Methylprednisolone in Elderly or Unfit Patients with Relapsed Chronic Lymphocytic Leukemia
Background and Objectives: BTK and BCL2 inhibitors have changed the treatment paradigms of high-risk and elderly patients with chronic lymphocytic leukemia (CLL), but their long-term efficacy and toxicity are still unknown and the costs are considerable. Our previous data showed that Rituximab (Rtx)...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6915691/ https://www.ncbi.nlm.nih.gov/pubmed/31671877 http://dx.doi.org/10.3390/medicina55110719 |
_version_ | 1783480075301158912 |
---|---|
author | Pileckyte, Regina Valceckiene, Vilma Stoskus, Mindaugas Matuzeviciene, Reda Sejoniene, Jurgita Zvirblis, Tadas Griskevicius, Laimonas |
author_facet | Pileckyte, Regina Valceckiene, Vilma Stoskus, Mindaugas Matuzeviciene, Reda Sejoniene, Jurgita Zvirblis, Tadas Griskevicius, Laimonas |
author_sort | Pileckyte, Regina |
collection | PubMed |
description | Background and Objectives: BTK and BCL2 inhibitors have changed the treatment paradigms of high-risk and elderly patients with chronic lymphocytic leukemia (CLL), but their long-term efficacy and toxicity are still unknown and the costs are considerable. Our previous data showed that Rituximab (Rtx) and high-dose methylprednisolone (HDMP) can be an effective and safe treatment option for relapsed high-risk CLL patients. Materials and Methods: We explored the efficacy and safety of a higher Rtx dose in combination with a shorter (3-day) schedule of HDMP in relapsed elderly or unfit CLL patients. Results: Twenty-five patients were included in the phase-two, single-arm trial. The median progression free survival (PFS) was 11 months (range 10–12). Median OS was 68 (range 47–89) months. Adverse events (AE) were mainly grade I–II° (77%) and no deaths occurred during the treatment period. Conclusions: 3-day HDMP and Rtx was associated with clinically meaningful improvement in most patients. The median PFS in 3-day and 5-day HDMP studies was similar and the toxicity of the 3-day HDMP schedule proved to be lower. The HDMP and Rtx combination can still be applied in some relapsed high-risk and elderly or unfit CLL patients if new targeted therapies are contraindicated or unavailable. (ClinicalTrials.gov identifier: NCT01576588). |
format | Online Article Text |
id | pubmed-6915691 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-69156912019-12-24 Dose Intensive Rituximab and High-Dose Methylprednisolone in Elderly or Unfit Patients with Relapsed Chronic Lymphocytic Leukemia Pileckyte, Regina Valceckiene, Vilma Stoskus, Mindaugas Matuzeviciene, Reda Sejoniene, Jurgita Zvirblis, Tadas Griskevicius, Laimonas Medicina (Kaunas) Article Background and Objectives: BTK and BCL2 inhibitors have changed the treatment paradigms of high-risk and elderly patients with chronic lymphocytic leukemia (CLL), but their long-term efficacy and toxicity are still unknown and the costs are considerable. Our previous data showed that Rituximab (Rtx) and high-dose methylprednisolone (HDMP) can be an effective and safe treatment option for relapsed high-risk CLL patients. Materials and Methods: We explored the efficacy and safety of a higher Rtx dose in combination with a shorter (3-day) schedule of HDMP in relapsed elderly or unfit CLL patients. Results: Twenty-five patients were included in the phase-two, single-arm trial. The median progression free survival (PFS) was 11 months (range 10–12). Median OS was 68 (range 47–89) months. Adverse events (AE) were mainly grade I–II° (77%) and no deaths occurred during the treatment period. Conclusions: 3-day HDMP and Rtx was associated with clinically meaningful improvement in most patients. The median PFS in 3-day and 5-day HDMP studies was similar and the toxicity of the 3-day HDMP schedule proved to be lower. The HDMP and Rtx combination can still be applied in some relapsed high-risk and elderly or unfit CLL patients if new targeted therapies are contraindicated or unavailable. (ClinicalTrials.gov identifier: NCT01576588). MDPI 2019-10-29 /pmc/articles/PMC6915691/ /pubmed/31671877 http://dx.doi.org/10.3390/medicina55110719 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Pileckyte, Regina Valceckiene, Vilma Stoskus, Mindaugas Matuzeviciene, Reda Sejoniene, Jurgita Zvirblis, Tadas Griskevicius, Laimonas Dose Intensive Rituximab and High-Dose Methylprednisolone in Elderly or Unfit Patients with Relapsed Chronic Lymphocytic Leukemia |
title | Dose Intensive Rituximab and High-Dose Methylprednisolone in Elderly or Unfit Patients with Relapsed Chronic Lymphocytic Leukemia |
title_full | Dose Intensive Rituximab and High-Dose Methylprednisolone in Elderly or Unfit Patients with Relapsed Chronic Lymphocytic Leukemia |
title_fullStr | Dose Intensive Rituximab and High-Dose Methylprednisolone in Elderly or Unfit Patients with Relapsed Chronic Lymphocytic Leukemia |
title_full_unstemmed | Dose Intensive Rituximab and High-Dose Methylprednisolone in Elderly or Unfit Patients with Relapsed Chronic Lymphocytic Leukemia |
title_short | Dose Intensive Rituximab and High-Dose Methylprednisolone in Elderly or Unfit Patients with Relapsed Chronic Lymphocytic Leukemia |
title_sort | dose intensive rituximab and high-dose methylprednisolone in elderly or unfit patients with relapsed chronic lymphocytic leukemia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6915691/ https://www.ncbi.nlm.nih.gov/pubmed/31671877 http://dx.doi.org/10.3390/medicina55110719 |
work_keys_str_mv | AT pileckyteregina doseintensiverituximabandhighdosemethylprednisoloneinelderlyorunfitpatientswithrelapsedchroniclymphocyticleukemia AT valceckienevilma doseintensiverituximabandhighdosemethylprednisoloneinelderlyorunfitpatientswithrelapsedchroniclymphocyticleukemia AT stoskusmindaugas doseintensiverituximabandhighdosemethylprednisoloneinelderlyorunfitpatientswithrelapsedchroniclymphocyticleukemia AT matuzevicienereda doseintensiverituximabandhighdosemethylprednisoloneinelderlyorunfitpatientswithrelapsedchroniclymphocyticleukemia AT sejonienejurgita doseintensiverituximabandhighdosemethylprednisoloneinelderlyorunfitpatientswithrelapsedchroniclymphocyticleukemia AT zvirblistadas doseintensiverituximabandhighdosemethylprednisoloneinelderlyorunfitpatientswithrelapsedchroniclymphocyticleukemia AT griskeviciuslaimonas doseintensiverituximabandhighdosemethylprednisoloneinelderlyorunfitpatientswithrelapsedchroniclymphocyticleukemia |